Board of Directors

Nicholas Rothwell

President & Co-Founder

Mr. Rothwell retired in December of 2022 and was previously the President of Buckingham Supply Chain Services, LLC, providing consulting services to the Biopharmaceutical industry.

Nick has been working in the life sciences industry for over 40 years and has acquired extensive experience, knowledge and expertise in Supply Chain, Logistics, Manufacturing and Operations Management during that time.

Prior to his consulting role, Rothwell was the EVP of Technical Operations at Archimedes Pharma, a privately held specialty pharmaceutical company with a diverse portfolio of products.  Nick was a member of the Global Leadership Team and an officer of the company.

Spanning a long career, Rothwell held senior level positions of increasing responsibility with Novartis, Pharmacia and Wyeth Pharmaceuticals where he contributed to the launch of the largest vaccine in the world.

Mr. Rothwell is a recognized leader in developing, implementing, and effectively managing end–to–end fully integrated supply chains and specializes in improving the overall performance across the supply network.  His primary focus is to manufacture a quality product, achieve competitive levels of service and ensure continuity of supply for a portfolio of products while effectively managing the costs associated with same.

Nick earned a technical degree in Materials Management while serving in the Royal Air Force and is certified in Production & Inventory Management by APICS, The Association for Operations Management.

As a relative of a patient, he is motivated and passionate about ensuring early detection through education and sponsoring research that achieves our objective of finding better treatment options and/or a cure.  Mr. Rothwell has dedicated his professional life to making a difference in and improving the quality of people’s lives.

Timothy Rothwell

President Emeritus & Co-Founder

Timothy G. Rothwell is currently the Chairman of Speracura LLC, a healthcare consulting company, which he founded in 2009.

Mr. Rothwell was previously the Chairman of Emisphere Technologies Inc. (OTC: EMIS), a commercial stage, specialty pharmaceutical company since early 2012 and prior to that a Director of the Company from late 2009.  The company was sold in December 2020.

Mr. Rothwell was formerly Chairman of Sanofi from February 2007 to October 2009 in the U.S.  He also served as Chief Executive Officer and President of Sanofi-Aventis from September 2004 to February 2007. Mr. Rothwell oversaw all domestic commercial operations as well as the coordination of Industrial Affairs and Research and Development activities in the U.S.  From May 2003 to September 2004, Mr. Rothwell was President and Chief Executive Officer of Sanofi-Synthelabo, Inc. and was instrumental in the formation of Sanofi-Aventis U.S. in 2004. Prior to that, from January 1998 to May 2003, he served in various capacities at Pharmacia, including as President of the company’s Global Prescription Business. From January 1995 to January 1998, Mr. Rothwell also served as worldwide President of Rhone-Poulenc Rorer Pharmaceuticals and President of the company’s Global Pharmaceutical Operations. In his long career, Mr. Rothwell has also served as Chief Executive Officer of Sandoz Pharmaceuticals, Vice President of Global Marketing and Sales at Burroughs Wellcome, and Senior Vice President of Marketing and Sales for the U.S. for Squibb Corporation which later became a Division of Bristol-Myers Squibb.

Mr. Rothwell holds a Bachelor of Arts from Drew University and earned his J.D. from Seton Hall University.

He formerly served on the PhRMA Board of Directors, as well as the Institute of Medicine’s Evidence-Based Medicine roundtable, the CEO Roundtable on Cancer, the Healthcare Businesswoman’s Association Advisory Board, the Board of Trustees for the Somerset Medical Center Foundation, the Board of Trustees for the HealthCare Institute of New Jersey, as a Trustee of the Corporate Council for America’s Children at the Children’s Health Fund, the Board of Directors of Agenus (NASDAQ: AGEN), the Board of Directors of Akrimax Pharmaceuticals LLC, Chairman of the Board of Directors of Archimedes Pharma LLC , Chairman of the Board of Directors of New American Therapeutics, and a member of the Board of Visitors for Seton Hall Law school.

He also served as the Chairman of the Pheo Para Alliance from 2009 to 2016, which is a non-profit organization dedicated to helping patients who suffer from pheochromocytoma and paraganglioma.

Xiaokui Zhang, Ph.D.

Vice President

Dr. Xiaokui Zhang has 20 years of progressive biopharmaceutical industry experience in research, discovery and development to advance programs into early clinical development. She joined Aspen Neuroscience, Inc. as Chief Scientific Officer and as a member of the company’s executive team in 2021 to lead the development of the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), as well as future platform and pipeline development for the autologous iPSC platform company.

Before joining Aspen, Dr. Zhang served as the Executive Vice President and Chief Scientific Officer at Celularity Inc., overseeing discovery, candidate development, preclinical, translational, process development and CMC activities to develop placenta-derived allogeneic, off-the-shelf cell therapy product candidates for immuno-oncology and functional regeneration applications. Dr. Zhang has also held various positions of increasing scope and responsibility at Celgene Cellular Therapeutics, including Director of Discovery Research and Senior Director of Research & Development. Before Celgene, Dr. Zhang led a gene discovery team at Helicon Therapeutics and conducted target identification studies in cognitive disorders.

Dr. Zhang’s research in functional characterizations of JAK-STAT signaling pathways and placental progenitor cell differentiation resulted in numerous patents and publications in highly ranked journals including Science. She has also served as a mentor to early-stage professionals in the International Society for Cell & Gene Therapy (ISCT), and is the honoree of New Jersey Liberty Science Center Women in Science, Technology, Engineering and Mathematics (STEM) Award.

Dr. Zhang received her undergraduate degree in Physiology from Nanjing University, Jingasu, China and her doctorate in Molecular Cell Biology from the Rockefeller University, New York, New York, with further post-doctoral training in the Functional Genomics at Novartis Pharmaceuticals.

 

Tiffany Hendry

Secretary

Accomplished career in special event planning, marketing, communications, brand building, product launch, digital & new media, creative design, project management, and copywriting.  Highly motivated, results-oriented professional with a demonstrated ability to drive and contribute to revenue growth and capitalize on new business potential. Delivers a unique set of skills to every engagement and operates effectively from a strategic perspective, as well as tactical execution.

Possesses skills in organizing and executing both internal and external communications, has gained event planning experience and the ability to create, develop and execute reports, newsletters, campaigns, publications, strategic communication plans, social media strategies and marketing sales tools.  As a generalist in Marketing, Public Relations and Event Planning, Tiffany puts her education, training and experience to work.  She continues to interface with both internal and external customers including associates, customers, vendors and government agencies both at the state and federal level.  Tiffany has the ability to work effectively with others both internally and externally at all levels within various organizations in a compliant manner.  She has a strong sense of responsibility & ability to work in cross functional teams and lead, is reliable and disciplined, and completes her tasks in a professional and timely manner.

In 2020, Tiffany launched Nova Rose Special Events, an Event Planning firm that serves the Hunterdon County, NJ region with the philosophy in mind that life is too short so we should celebrate it.  Nova Rose Special Events helps create memories that will last a lifetime.  Tiffany plans, decorates & runs events whether it is a small private gathering or a large charity event.  Attention to detail is her main priority because every single detail big or small matters.  She has always had a deep passion for organizing and planning, and truly believes every special event deserves to be stunning.  Tiffany uses her creativity and years of experience to make each celebration unforgettable.

Antony Rothwell

Treasurer

Antony Rothwell has worked in the pharmaceutical industry for over 15 years where he has focused on face-to-face marketing and compliance. His experiences at Novo Nordisk, Genentech, Sanofi-Aventis, and Reliant Pharmaceuticals span multiple therapeutic areas including primary care, oncology, neurology and rare disease.

Antony is a recognized leader in the healthcare convention and exhibition space and currently serves on the Healthcare Convention & Exhibitions Association (HCEA) Board of Directors.

Antony is motivated by improving the lives of others and is committed to contributing to physician and patient education about Paraganglioma’s and Pheochromocytoma’s respectively.

Rick Keefer

Board Director

Rick is a 30-year industry veteran with broad-based experience in leading commercial operations. He is now leading a technology company focused on enhancing health education and enablement. In addition he is engaged in the nutraceutical area with a healthy energy supplements and drinks company.

In previous roles, Mr. Keefer was Global Chief Business Development Officer at Publicis Health, Senior Vice President, Commercial Operations with Biovail Corporation and Vice President, Sales for Pharmacia Corporation. Prior to Pharmacia, Rick spent 11 years at Wyeth where he held a number of senior positions in both of the company’s institutional and primary care divisions.

Rick is passionate about the vital contribution the biopharma industry makes in helping people live longer and healthier lives. He holds a deep-seated belief that our calling is upright, benevolent, and admirable. According to Rick, every member of a health focused company should sleep well at night knowing that the work they do each day has a positive effect on the lives of people in their nation, community, and family. It’s an honor and privilege we take seriously.

Sheila Buchbinder, MD

Board Director

Dr. Buchbinder joined the board of directors with extensive experience as a board-certified obstetrician gynecologist.

In addition, her private practice specialized in laparoscopic surgery.

She has acted as a consultant both at the state and federal level in relation to women’s healthcare issues.

She has taught and published on laparoscopic surgery and participated in the design and development of innovative medical technologies.

Dr. Buchbinder has received the American Woman’s Medical Association and Lang Publication awards.

Dr. Buchbinder is a graduate of Brown University’s Program in Medicine and completed her training at Columbia Presbyterian Medical Center, Sloane Hospital for Women.

Curtis Quigley

Board Director

Curtis Quigley is a senior biopharmaceutical  and medical device executive with more than twenty five years experience within the commercial operations and global health access segments of the industry.

Most recently, Curtis was Senior Vice President of Commercial Operations for Celularity, Inc.  Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from postpartum human placenta, in cancer immunotherapy and functional regeneration.

Prior to joining Celularity Inc. Curtis was Vice President and General Manager, Global Health and Access and Vice President of Sales Operations and Integrated Health for Celgene Corporation (acquired by Bristol-Myers Squibb Company).

Previous to Celgene Corporation, he held leadership positions at Pharmacia, Rhone-Poulenc Rohr and Novartis.

Board Director / Website Administrator

Adam Hooper is the Associate Director of Market Access and Reimbursement at Novartis Pharmaceuticals Corporation.  In this role, Adam supports the Novartis Neurology portfolio working closely with the MS franchise and is responsible for patient’s ability to access their medication.

Bringing over 12 years of experience in the pharmaceutical industry, Adam joined Novartis in 2020 as Field Reimbursement Manager.  Prior to that, he held increasing roles of responsibility including sales roles in therapeutics, pain management, gastroenterology, respiratory and diabetes divisions for AstraZeneca.  He has also supported patients from an access and reimbursement perspective with United Bio-source Corporation and Syneos Health as Field Reimbursement Manager supporting nephrology and most recently, neurology.

Adam has a true passion and motivation to help patients across many different disease states by ensuring patients have access to their medications. This is demonstrated by his outstanding performance winning numerous awards, including Presidents Club for two consecutive years.

He is also extremely interested in rare disease and has become a Board Member in the SDHB PheoPara Coalition to raise awareness, educate healthcare professionals and patients, and raise funds to find better treatment options and/or a cure.

In addition to his pharmaceutical work, Adam has his New Jersey Soccer Coaching F License and has previously coached numerous young men’s soccer teams.

Born in Exeter, England, Adam moved to New Jersey as a child, lived in California for a short time, and then returned to New Jersey to raise his two children with his wife.

Adam holds a bachelor’s degree in Business Marketing from William Patterson University in New Jersey.